Abstract
Thrombolytic agents play a major role in the treatment of cardiovascular diseases. Streptokinase is the prominently commercialized thrombolytic drug used for the treatment of cardiovascular diseases. The later studies on staphylokinase (SaK) showed promising results as an alternative fibrinolytic drug. The present study explores the isolation, production and purification of SaK producing Staphylococcus sp. from milk samples. The potent isolate MSA4 of Staphylococcus sp. was selected for production and purification of SaK. The total activity and specific activity of purified staphylokinase was found to be 1266 IU mL-1 and 815.5 IU mg-1, respectively. The partially purified enzyme was lysed the euglobulin clot completely within 18 h of incubation and the purified enzyme showed 79% of blood clot lysis activity.
Keywords: Clot buster, euglobulin clot, Staphylococcus sp., staphylokinase.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Evaluation on Clot Buster Activity of Staphylokinase from Staphylococcus sp.
Volume: 12 Issue: 2
Author(s): V. Mohanasrinivasan, C. Subathra Devi, Sukanya Saha, Lubbnaz Nagarchi, B. Vaishnavi and S. J. Naine
Affiliation:
Keywords: Clot buster, euglobulin clot, Staphylococcus sp., staphylokinase.
Abstract: Thrombolytic agents play a major role in the treatment of cardiovascular diseases. Streptokinase is the prominently commercialized thrombolytic drug used for the treatment of cardiovascular diseases. The later studies on staphylokinase (SaK) showed promising results as an alternative fibrinolytic drug. The present study explores the isolation, production and purification of SaK producing Staphylococcus sp. from milk samples. The potent isolate MSA4 of Staphylococcus sp. was selected for production and purification of SaK. The total activity and specific activity of purified staphylokinase was found to be 1266 IU mL-1 and 815.5 IU mg-1, respectively. The partially purified enzyme was lysed the euglobulin clot completely within 18 h of incubation and the purified enzyme showed 79% of blood clot lysis activity.
Export Options
About this article
Cite this article as:
Mohanasrinivasan V., Devi Subathra C., Saha Sukanya, Nagarchi Lubbnaz, Vaishnavi B. and Naine S. J., Evaluation on Clot Buster Activity of Staphylokinase from Staphylococcus sp., Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (2) . https://dx.doi.org/10.2174/1871525712666141106102809
DOI https://dx.doi.org/10.2174/1871525712666141106102809 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Prodrugs to Codrugs
Current Drug Therapy Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery Centenarian Offspring: A Model for Understanding Longevity
Current Vascular Pharmacology Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.
Current Clinical Pharmacology Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?
Current Pharmaceutical Design Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Chlorine, Chlorination By-Products and Their Allergic and Respiratory Health Effects
Current Respiratory Medicine Reviews Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Supramolecular Nanomedicine - An Overview
Current Drug Targets Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
Cardiovascular & Hematological Agents in Medicinal Chemistry IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews